Seminars in Pediatric Neurology
Volume 15, Issue 3 , Pages 132-139, September 2008

Neurologic Damage and Neurocognitive Dysfunction in Urea Cycle Disorders

  • Gregory M. Enns, MB, ChB

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Gregory M. Enns, MB, ChB, Division of Medical Genetics, Stanford University, 300 Pasteur Drive, H-315, Stanford, CA 94305

Department of Pediatrics, Division of Medical Genetics, Lucile Packard Children's Hospital, Stanford University, Stanford, CA

Although the survival of patients who have urea cycle disorders has improved with the use of modalities such as alternative pathway therapy and hemodialysis, neurologic outcome is suboptimal. Patients often manifest with a variety of neurologic abnormalities, including cerebral edema, seizures, cognitive impairment, and psychiatric illness. Current hypotheses of the pathogenesis underlying brain dysfunction in these patients have focused on several lines of investigation, including the role of glutamine in causing cerebral edema, mitochondrial dysfunction leading to energy failure and the production of free radicals, and altered neurotransmitter metabolism. Advances in understanding the pathogenetic mechanisms underlying brain impairment in urea cycle disorders may lead to the development of therapies designed to interfere with the molecular cascade that ultimately leads to cerebral edema and other brain pathological findings.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 10.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr Enns reports serving on the Scientific Advisory Board and being on the speaker's bureau for Hyperion Therapeutics, Inc.

PII: S1071-9091(08)00050-8

doi:10.1016/j.spen.2008.05.007

Seminars in Pediatric Neurology
Volume 15, Issue 3 , Pages 132-139, September 2008